Anaptys Biosciences, Inc. is a privately-held developer of therapeutic antibody products and the leader in the use of SHM for antibody discovery and optimization. SHM, or somatic hypermutation, is the natural process our bodies use for generating antibody diversity to fight disease. Our Omnitope-SHM™ System utilizes the key components of SHM and flow cytometry technology to enable the rapid variation and selection of antibodies with enhanced bioactivities. In addition to providing a more powerful approach to antibody discovery and protein optimization, it addresses a growing void in the therapeutic antibody field due to a string of acquisitions and licensing deals that have reduced the availability of many technologies.

Our team has extensive technical and business experience in the development and commercialization of therapeutic antibodies and other biopharmaceuticals. We have established broad intellectual property around SHM and the Omnitope-SHM™ System, and are building a pipeline of novel therapeutic antibodies with significant medical and commercial potential.